Pulmonary Arterial Hypertension Global Market 2024 – By Demand, Growth, Trends, Share, Forecast To 2033 | United Therapeutics Corporation, Acceleron Pharma Inc., Actelion Pharmaceuticals US Inc

Pulmonary Arterial Hypertension
Spread the love

The pulmonary arterial hypertension market size is expected to see strong growth in the next few years. It will grow to $11.99 billion in 2028 at a compound annual growth rate (CAGR) of 8.8%.  The growth in the forecast period can be attributed to adoption of novel therapies for pulmonary arterial hypertension, increased focus on early detection and diagnosis, growing pipeline of pah drugs and therapies, integration of precision medicine in pah treatment, expansion of healthcare infrastructure in emerging markets. Major trends in the forecast period include advancements in medical imaging and diagnostic technologies, collaboration and partnerships for drug development, patient-centric approaches in pulmonary arterial hypertension management, increased use of combination therapy.

To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/pulmonary-arterial-hypertension-global-market-report

Segmentation & Regional Insights
The pulmonary arterial hypertension market covered in this report is segmented –

1) By Drug Class: Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators
2) By Route of Administration: Oral, Intravenous/ subcutaneous, Inhalational
3) By Distribution channel: Retail, Online

North America was the largest region in the pulmonary arterial hypertension market in 2023. The regions covered in the pulmonary arterial hypertension market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=5954&type=smp

Major Driver Impacting Market Growth
The increasing prevalence of pulmonary arterial hypertension (PAH) disease is contributing to the growth of the pulmonary arterial hypertension market. The increasing prevalence of PAH diseases and the related hospitalization of patients for treatment is expected to boost the demand for relevant drugs during the forecast period. According to a study published by the National Organization for Rare Disorders, Inc., new cases of PAH are estimated to occur in one to two individuals per million each year in the USA, which equates to 500–1000 new cases each year, and Europe is expected to have similar incidence rates.

Key Industry Players
Major companies operating in the pulmonary arterial hypertension market report are United Therapeutics Corporation, Acceleron Pharma Inc., Actelion Pharmaceuticals US Inc., Bayer AG, Eli Lilly and Company, Gilead Sciences Inc., GlaxoSmithKline plc, Johnson & Johnson, Liquidia Technologies Inc., Lupin Pharmaceuticals Inc., Natco Pharma Ltd., Pfizer Inc., Sandoz AG, Teva Pharmaceutical Industries Ltd., Zydus Pharmaceutical USA Inc., Allegheny Health Network, Cedars-Sinai Medical Center, Cleveland Clinic, Houston Methodist Hospital, Johns Hopkins Medicine, Massachusetts General Hospital, Mayo Clinic, MedStar Heart & Vascular Institute, National Jewish Health, NewYork-Presbyterian Hospital, Ochsner Medical Center, Royal Brompton & Harefield NHS Foundation Trust, Rush University Medical Center, Stanford Health Care, Swedish Medical Center, Temple University Hospital, University of California Health.

The pulmonary arterial hypertension market report table of contents includes:
1. Executive Summary
2. Pulmonary Arterial Hypertension Market Characteristics
3. Pulmonary Arterial Hypertension Market Trends And Strategies
4. Pulmonary Arterial Hypertension Market – Macro Economic Scenario
5. Global Pulmonary Arterial Hypertension Market Size and Growth
……………..
31. Global Pulmonary Arterial Hypertension Market Competitive Benchmarking
32. Global Pulmonary Arterial Hypertension Market Competitive Dashboard
33. Key Mergers And Acquisitions In The Pulmonary Arterial Hypertension Market
34. Pulmonary Arterial Hypertension Market Future Outlook and Potential Analysis
35. Appendix

Explore the trending research reports from TBRC:
https://goodprnews.com/farm-animal-healthcare-global-market-size/
https://goodprnews.com/fraud-hunters-global-market-size/
https://goodprnews.com/hand-held-chemical-and-metal-size/
https://topprnews.com/farm-animal-healthcare-global-market-share/
https://topprnews.com/fraud-hunters-global-market-share/
https://topprnews.com/hand-held-chemical-and-metal-share/

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]

Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model


Spread the love

About Top PR News

TopPRnews Leads Drives Search Engine Visibility For Your Press Release Content. Our Global Network Reaches Important Contacts, Media Partners And Websites And Journalists. Happy Postings! If You Have Any Queries Please Contact Official Mail At [[email protected]}

View all posts by Top PR News →

Leave a Reply

Your email address will not be published. Required fields are marked *